Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer

Clinical trial NCT03936465 · COMPLETED

Trial details

NCT number: NCT03936465
Sponsor: Dana-Farber Cancer Institute
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumor, Childhood Lymphoma Brain Tumor, Pediatric

Start date: 2019-09-27
Primary completion: 2024-03-16
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.